X

Adapted01 Breast Cancer for Android

Developer's Description

Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS 25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].

Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS 25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].

Full Specifications

What's new in version 1.0

General

Release October 9, 2020
Date Added October 9, 2020
Version 1.0

Operating Systems

Operating Systems Android
Additional Requirements Requires Android 5.0 and up

Popularity

Total Downloads 0
Downloads Last Week 0
Report Software

Related Apps

Fitbit logo

Fitbit

Free
Fitbit
Calorie Counter - MyFitnessPal logo

Calorie Counter - MyFitnessPal

Free
Calorie Counter - MyFitnessPal
Medscape logo

Medscape

Free
Medscape
Epocrates logo

Epocrates

Free
Epocrates

Get the best price on everything

Shop your favorite products and we’ll find the best deal with a single click. Designed to make shopping easier.